Archive | Redefining Early Stage Investments RSS feed for this section

Onelin PitchBuzz: Live Q&A

17 Sep

By Candice He, Global Investment Strategist, LSN

ONELIN Capital Corporation is a multi-billion-dollar conglomerate seeking to partner with impressive early-stage lifescience companies interested in working in the Asian market. As a title sponsor of Digital RESI September, Onelin has selected 20 companies to pitch directly to their panel of investors.

This is a powerful opportunity, not only for the selected finalists, but also for the entire RESI community to view and participate as attendees. We encourage all RESI participants to check out these LIVE pitch sessions next week:

September 21, 12:00 PM – 12:50 PM

Onelin PitchBuzz Session 1 – Therapeutics

September 21, 01:00 PM – 01:50 PM

Onelin PitchBuzz Session 2 – Therapeutics

September 23, 12:00 PM – 12:50 PM

Onelin PitchBuzz Session 3 – Medtech Devices

September 23, 01:00 PM – 01:50 PM

Onelin PitchBuzz Session 4 – Healthcare IT/Digital Health

Congratulations to Our Digital RESI September Innovation Challenge Winners!

17 Sep

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day Digital Redefining Early Stage Investments (RESI) September Conference came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovation Challenge. Each participating finalist company had a dedicated page featuring a virtual poster, short pitch, and other supplementary materials available for viewing.

The Digital RESI September Live Agenda is open to registered attendees until October 14, so there’s still time to check out the Digital RESI September Live Agenda for virtual exhibit of innovative technologies across all life science & healthcare sectors!

The RESI Team would like to thank every Innovation Challenge company for their virtual presentations, and the hard work to promote their technologies to our RESI community. The Top 3 winners will be awarded with free tickets to future RESI conferences. Congratulations to the Top 3 winners, and thanks to all for voting!

First Place: SentiAR

SentiAR (St. Louis, MO) is developing the first application of Mixed Reality technology for use during cardiac ablation procedures, including the treatment of atrial fibrillation. The SentiAR platform provides an immersive command-center for the clinicians by presenting a 3D hologram of the patient’s electroanatomic data via the Microsoft HoloLens in real-time. Our solution gives the clinician unprecedented control via SentiAR’s patent protected, intuitive gaze interface and provides invaluable insight to guide physician diagnosis and catheter placement.

 

Second Place: InvivoSciences

Madison, WI based InvivoSciences (IVS) is a pre-clinical-stage biotech company developing heart failure (HF) therapeutics using a precision medicine approach to extend lifespan of patients.  Our mission is to cure heart failure one gene at a time. It is driven by the urgency of heart failure patients who need more effective and safe therapies.

Our Breakthrough platform discovery technology rapidly analyzes safety and efficacy profile of a given treatment for specific patient group cost-effectively before expensive trials. IVS matchmakes the best treatment for the patient group and expedites the early discovery, clinical trials, and post-product launch monitoring, bringing tremendous value before investing significant resources in human trials.

We have leveraged our breakthrough precision medicine discovery platform using patient-derived human micro heart on a chip Nuheart TM to identify and validate multiple drug pipelines rapidly.

Collaborative patient-driven precision medicine-based drug development empowered with our novel platform can lead to meaningfully better outcomes for heart failure patients, which we refer as InvivoSciences’ discovery engine to develop target therapies. To help move our programs forward InvivoSciences is seeking world class life science investors and strategic partners.

 

Third Place: Cybrexa Therapeutics 

Cybrexa Therapeutics is a private oncology-focused biotech developing a new class of therapeutics based on our alphalex™ platform.

The company anticipates its lead program, CBX-12 (alphalex™-exatecan), will enter Phase I/II in early 2021.  CBX-12 is an alphalex™ conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 was selected based on its strong efficacy and solid  safety profile demonstrated to date in preclinical studies. CBX-12 has potential synergy with PD-1 inhibitors and other immuno-oncology drugs. Cybrexa plans to publish preclinical data for CBX-12 in the first half of 2020 and to advance the program into the clinic in 2021, with clinical efficacy and safety data expected by 2022.

Next Week LSN Debuts Two Back-to-Back Partnering Events: Digital RESI September & 4D Meets AI

10 Sep

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN) extends its theme of matching early-stage scientist-entrepreneurs with investors and strategic partners with two September conferences launching next week: Digital Redefining Early Stage Investments (RESI) and the Inaugural 4D Meets AI. Digital RESI will take place September 14-16, followed by 4D Meets AI, September 17-18. LSN’s partnering events are unique their matching buyers and sellers based on stage of development and product set. Having meetings that are pre-matched based on fit creates dynamic interactions between fundraising CEOs and potential global partners.

Panels & Workshops

Check out our impressive panels and workshops aimed at aiding early-stage CEOs as they navigate the fundraising the funding landscape, while also providing insight for investors and strategic partners into the latest tech and industry developments.

Digital RESI Sept. Investor Panel Agenda | 4D Meets AI Panel Agenda

Partnering

LSN expects over 500 global investors at these two events seeking new technology assets for their portfolios. LSN’s partnering events are international in scope and include companies across the silos of drugs, devices, diagnostics and digital health. It’s not too late to attend and use the weekend to book meetings! Sign up to take part of this one-of-a-kind cross-border partnering week.

Check RESI Website Here  |  Check 4D Meets AI Website Here

Digital RESI Featured Company Pitch Sessions

10 Sep

By Karen Deyo, Senior Investor Research Analyst, LSN

The RESI Featured Company Pitch Session is a great opportunity for companies to showcase their technologies. Companies participating in the FCPS have a dedicated page that features their pitch which is highlighted in the RESI Digital Agenda, as well as on their partnering page. Additionally, companies will have an opportunity to have a live Q&A session with a panel of relevant investors. Of our six pitch sessions, three of them are funded by the NIH, with two sessions featuring companies from the SEED program, and one session featuring companies sponsored by NCI. Check out all of the FCPS companies below, and make sure to check out the live Q&A sessions!

  • Therapeutics, Monday, September 14, 12PM EST
  • SEED, Monday, September 14, 4PM EST
  • Therapeutics, Tuesday, September 15, 12PM EST
  • SEED, Tuesday, September 15, 4PM EST
  • Medical Device, Wednesday, September 16, 12PM EST
  • NCI, Wednesday, September 16, 4PM EST


Next Week’s Live Panel Schedule, Part of Digital RESI September 2020

10 Sep

By Joey Wong, Investor Research Analyst, LSN

Digital RESI September is off to a great start, but we’re not slowing down! We will be hosting a second week of live investor panels. Check out next week’s lineup, and register here for RESI September 2020 to participate in these live panels!

All panels at Digital RESI September are live-streamed. There will be two live panel sessions each day through the end of the conference, September 8-16. We welcome all Digital RESI September attendees to join and participate in these live sessions. Registered attendees can RSVP via the partnering platform to receive the dial-in information to join. For those who cannot make the live sessions, all the panel videos will be available via the virtual agenda.

Digital RESI September registrants will hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and much more.

Below is the schedule for next week’s live panel sessions:

Diagnostics Investors PanelNew Generation of Technologies Changing Treatment Paradigms

Monday, September 14, 10:00 – 10:50 am EST

  • Nola Masterson (Moderator), Managing Director, Science Futures
  • Katherine Hill Richie, Director, Nottingham Spirk Family Office
  • Michele Colucci, Managing Partner, DigitalDx Ventures
  • Rick Jones, Partner, BioAdvance

Big Pharma PanelPipeline Strategy for Preclinical and Early Clinical Assets

Monday, September 14, 2:00 – 2:50 pm EST

  • Chris Haskell (Moderator), Vice President, Head of West Coast Innovation Center, Bayer
  • Fiona Mack, Head of JLABS TMCx, Johnson & Johnson Innovation
  • Jessica Droge, Executive Director, Business Development, Amgen
  • Michel de Baar, Executive Director, BD&L, Early Stage Search & Evaluation, MSD
  • Natalia Novac, Director, Emerging Technology & Innovation, Eli Lilly & Co

Medical Device Investors PanelInvesting in Novel Engineering

Tuesday, September 15, 10:00 – 10:50 am EST

  • Greg Mannix (Moderator), VP of Global Business Development, Life Science Nation
  • Benedikt Luhmann, Principal, VI Partners
  • Norm Gitis, Founder & Managing Partner, Lymo Ventures
  • Shy Zymann, Partner, Catalyst Investments
  • William Dai, Founding Partner, ShangBay Capital
  • Yoke Sin, Managing Partner, IGlobal Partners

Early Stage Therapeutics Investors PanelBringing the Newest Therapies to the Clinic

Tuesday, September 15, 2:00 – 2:50 pm EST

  • Scott Weiner (Moderator), Partner, Amzak Health
  • Bettina Ernst, Partner, BERNINA BioInvest
  • Bibhash Mukhopadhyay, Principal, New Enterprise Associates
  • Jayson Punwani, Senior Partner, Takeda Ventures
  • Sascha Berger, Partner, TVM Capital Life Science

Family Offices & Angel Investors PanelThe Search for New Approaches to Diagnosing & Treating Caner

Wednesday, September 16, 10:00 – 10:50 am EST

  • Laura Davis, Managing Director, Golden Seeds
  • Marcia Dawood, Managing Partner, Individual Angel
  • Merom Klein, Entrepreneur Mentor, Keiretsu Forum
  • Rob Manning, Chairman, Cherrystone Angel Group
  • Ron Pallwoda, Founder & President, Pallwoda Group

Digital Health Investors PanelLeveraging Software to Lower Costs and Improve the Quality of Care

Wednesday, September 16, 2:00 – 2:50 pm EST

  • Ben Evans, Investment Director, InHealth Ventures
  • Evan Cohen, Associate Principal, Strategic Investing, Healthbox
  • Netalie Nadivi, Partner, TriVentures
  • Pierre Socha, Partner, Amadeus Capital Partners
  • Robert Garber, Partner, 7wire Ventures

Digital RESI September Innovation Challenge Finalists

3 Sep

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claire

With the Digital RESI September conference less than two weeks away, Life Science Nation (LSN) is thrilled to announce the Innovation Challenge finalist companies!

These companies were selected based on innovative technology, strong management team, clear pathway to commercialization, and additional factors demonstrating high-growth potential.

As part of the digital Innovation Challenge, each company will have a dedicated webpage as part of our virtual conference agenda. These pages will feature a virtual poster with additional materials highlighting their products and technology.

Attendees can vote for their favorite technologies throughout the three-day conference, and the top three finalists will be announced on Wednesday, September 16 and featured on our weekly newsletter of over 36,000 subscribers on Thursday, September 17.

The RESI community appreciates all applicants for adding value to the event through the Innovation Challenge. If you haven’t yet signed up for Digital RESI September to participate, there is still time! You can register here for the opportunity to learn more about these impressive companies and vote for your favorite.

Congratulations to the selected finalists – please click the below logos to learn more about them!

Therapeutics

Medical Devices

Diagnostics

Digital Health

Live Panel Schedule for Digital RESI September 2020

3 Sep

By Joey Wong, Investor Research Analyst, LSN

With only one week left, Digital RESI September 2020 is right around the corner! We are very excited to announce the live panel schedule for the conference.

All panels at Digital RESI September will be live-streamed. There will be two live panel sessions each day, starting as early as next week and will continue through the end of the conference, September 8-16. We welcome all Digital RESI September attendees to join and participate in these live sessions. Registered attendees can RSVP via the partnering platform to receive the dial-in information to join. For those who cannot make the live sessions, all the panel videos will be available via the virtual agenda.

It is worth noting that Global Investment and Partnership Panel, sponsored by Onelin Capital, is open to the public (no RESI registration required). Interested readers are welcome to RSVP here and participate in this panel.

Digital RESI September registrants will hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and much more. If you haven’t already, register here for RESI September 2020 to participate in these live panels!

Below is the schedule for next week’s live panel sessions:

 

Corporate VC Panel – “The Corporate Landscape Morphed & New Opportunities Abound

Date & Time: Tuesday, September 8, 10:00 – 10:50 am EST

  • Andy Merken (Moderator), Partner and Co-Chair, Life Sciences, Burns & Levinson
  • Lana Ghanem, Managing Director, Hikma Ventures
  • Mark Ralph, Executive Director, Boehringer Ingelheim Venture Fund
  • Tom Gibbs, Director, Debiopharm Innovation Fund

Medtech Strategics Panel“Large Medical Device Firms Seeking External Innovation”

Date & Time: Tuesday, September 8, 12:00 – 12:50 pm EST

  • Geoff Dacosta (Moderator), Director of Business Development and Licensing, Medtronic
  • Christina Salys, Director of New Business development, Intuitive Surgical
  • David Uffer, Senior Partner, Alira Ventures
  • Rupert Winckler, Head of EMEA New Business Development, Olympus Corporation

Health System Partners Panel “Care Providers and Payers Seek New Technologies”

Date & Time: Wednesday, September 9, 12:00 – 12:50 pm EST

  • Cyrll Philip, Principal, Providence Ventures
  • Linda Maxwell, Director, Biomedical Zone
  • Mayank Taneja, Director of Venture Investments, OSF Healthcare Ventures
  • Rajesh Aggarwal, Executive Vice President, Jefferson Strategic Ventures

Seed Funds Panel “Investing in Emerging Science to Pursue High Rewards”

Date & Time: Wednesday, September 9, 2:00 – 2:50 pm EST

  • Gary Gershony (Moderator), Life Science Angels
  • Anya Roy, Head of Illumina Accelerator Cambridge, Illumina Accelerator
  • Jun Deng, Investment Partner, Joyance Partners
  • Nancy Kaufman, CEO, Beacon Capital
  • Prathna Ramesh, Executive Director, Maple Leaf Angels

Oncology Innovation Panel – “The Search for New Approaches to Diagnosing & Treating Cancer”

Date & Time: Thursday, September 10, 12:00 – 12:50 pm EST

  • Steve Yoder (Moderator), Vice President of Business Development, Taiho Oncology
  • Anthony Bajoras, Managing Director, Cancer Fund
  • Barbara Lavery, Chief Program Officer, Alliance for Cancer Gene Therapy
  • Duncan Young, Director of Search and Evaluation Oncology, Business Development & Licensing, AstraZeneca
  • Mark Krul, Partner, Aglala Oncology Fund

Global Investment and Partnership Panel “Asia Firms Looking to Build Global Partnerships”

Date & Time: Thursday, September 10, 8:00 – 8:50 pm EST (Sponsored by Onelin Capital, Open to the public)

  • Judy Lee (Moderator), General Manager, Onelin Capital
  • Haolin Sung, Managing Partner, Chaperone Investment
  • Haruhiko Sugino, Director of Global Business Development, Otsuka Pharmaceuticals
  • Weiyong Sun, Senior Director of Specialty Medicine Search & Evaluation, Daichi Sankyo
  • Yao Li Ho, Senior Director of Business Development, LYFE Capital

Impact Investors Panel – “Life Science Investors Looking for More Than Financial Returns”

Date & Time: Friday, September 11, 12:00 – 12:50 pm EST

  • Lore Gruenbaum (Moderator), Vice President of Therapy Acceleration Program, Leukemia & Lymphoma Society
  • Chris Penland, Vice President of BioPharma Programs, Cystic Fibrosis Foundation
  • Kuldip Dave, Vice President of Research, ALS Association
  • Michael Cole, Founder and General Partner, Global Neurohealth Ventures
  • Paul Larkin, Manager of Research Innovation, Crohn’s and Colitis Foundation

%d bloggers like this: